{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:58:55Z","timestamp":1762865935876,"version":"3.41.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/igc.0b013e31824b403d","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T06:02:36Z","timestamp":1331877756000},"page":"762-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?"],"prefix":"10.1016","volume":"22","author":[{"given":"James Stuart","family":"Ferriss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin R.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Courtney-Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton T.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31824b403d_bb0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0010","first-page":"1","article-title":"Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases","volume":"37","author":"Aure","year":"1971","journal-title":"Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0015","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0020","first-page":"235","article-title":"Role of cytoreductive surgical treatment in the management of advanced ovarian cancer","volume":"63","author":"Griffiths","year":"1979","journal-title":"Cancer Treat Rep."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2010.06.021","article-title":"The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists","volume":"119","author":"Dewdney","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ijgc-00009577-200311001-00006","article-title":"The potential role of neoadjuvant chemotherapy in advanced ovarian cancer","volume":"13","author":"Baekelandt","year":"2003","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","article-title":"Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease","volume":"105","author":"Hou","year":"2007","journal-title":"Gynecol Oncol."},{"author":"Obesity and Overweight for Professionals","key":"10.1097\/IGC.0b013e31824b403d_bb0050"},{"key":"10.1097\/IGC.0b013e31824b403d_bb0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ajog.2006.03.075","article-title":"Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III\/IV epithelial ovarian cancer","volume":"195","author":"Everett","year":"2006","journal-title":"Am J Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2006.10.055","article-title":"Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system","volume":"105","author":"Aletti","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2007.03.008","article-title":"Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer","volume":"106","author":"Geisler","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0070","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ygyno.2006.06.019","article-title":"Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer","volume":"103","author":"Alphs","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","article-title":"Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon","volume":"100","author":"Aletti","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0085","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00006250-198606000-00007","article-title":"Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity","volume":"67","author":"Heintz","year":"1986","journal-title":"Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e31824b403d_bb0090","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1200\/JCO.2007.12.2317","volume":"25","author":"Chi","year":"2007","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24088108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24088108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:18:05Z","timestamp":1753233485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24088108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1048891X24088108"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31824b403d","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31824b403d","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2012 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}